Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Bap29varP, a variant of Bap29, influences the cell surface expression of the human P-glycoprotein.

Rao PS, Bickel U, Srivenugopal KS, Rao US.

Int J Oncol. 2008 Jan;32(1):135-44.

PMID:
18097552
2.

Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells.

Molinari A, Calcabrini A, Meschini S, Stringaro A, Crateri P, Toccacieli L, Marra M, Colone M, Cianfriglia M, Arancia G.

Curr Protein Pept Sci. 2002 Dec;3(6):653-70. Review.

PMID:
12470219
4.

Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells.

Kim H, Barroso M, Samanta R, Greenberger L, Sztul E.

Am J Physiol. 1997 Aug;273(2 Pt 1):C687-702.

PMID:
9277367
6.

Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression.

Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR.

Mol Pharmacol. 2010 Aug;78(2):310-8. doi: 10.1124/mol.109.061713.

7.

Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.

Kang DI, Kang HK, Gwak HS, Han HK, Lim SJ.

Drug Deliv. 2009 Jul;16(5):261-7. doi: 10.1080/10717540902937562.

PMID:
19538007
8.

MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential.

Luker GD, Flagg TP, Sha Q, Luker KE, Pica CM, Nichols CG, Piwnica-Worms D.

J Biol Chem. 2001 Dec 28;276(52):49053-60.

10.

Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines.

Gómez-Martínez A, García-Morales P, Carrato A, Castro-Galache MD, Soto JL, Carrasco-García E, García-Bautista M, Guaraz P, Ferragut JA, Saceda M.

Mol Cancer Res. 2007 Jun;5(6):641-53.

11.

Membrane topology of the N-terminal half of the hamster P-glycoprotein molecule.

Zhang JT, Duthie M, Ling V.

J Biol Chem. 1993 Jul 15;268(20):15101-10.

12.

Activation of the human P-glycoprotein ATPase by trypsin.

Nuti SL, Mehdi A, Rao US.

Biochemistry. 2000 Mar 28;39(12):3424-32.

PMID:
10727237
13.

Characterization of a new antibody raised against the NH2 terminus of P-glycoprotein.

Rao PS, Govindarajan R, Mallya KB, West W, Rao US.

Clin Cancer Res. 2005 Aug 15;11(16):5833-9.

14.

An N-terminal diacidic motif is required for the trafficking of maize aquaporins ZmPIP2;4 and ZmPIP2;5 to the plasma membrane.

Zelazny E, Miecielica U, Borst JW, Hemminga MA, Chaumont F.

Plant J. 2009 Jan;57(2):346-55. doi: 10.1111/j.1365-313X.2008.03691.x.

15.

Varied expression and localization of multiple galectins in different cancer cell lines.

Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS, Rao US.

Oncol Rep. 2008 Mar;19(3):587-94.

PMID:
18288388
16.

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.

Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP.

Mol Cancer Ther. 2008 Jul;7(7):2152-9. doi: 10.1158/1535-7163.MCT-08-0021.

18.

The Nrf3 transcription factor is a membrane-bound glycoprotein targeted to the endoplasmic reticulum through its N-terminal homology box 1 sequence.

Zhang Y, Kobayashi A, Yamamoto M, Hayes JD.

J Biol Chem. 2009 Jan 30;284(5):3195-210. doi: 10.1074/jbc.M805337200.

19.
20.

Supplemental Content

Support Center